ASLAN Pharmaceuticals Completes Recruitment in Phase 2b TREK-AD Study of Eblasakimab
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
ASLAN Pharmaceuticals Completes Recruitment in Phase 2b TREK-AD Study of Eblasakimab
Read at investing.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
NAMS | NewAmsterdam Pharma | 41.41 | ||||
CMPX | Compass Therapeutics | 7.88 | ||||
LYRA | Lyra Therapeutics | 5.00 | ||||
ACRV | Acrivon Therapeutics, | 3.63 | ||||
IVA | Inventiva | 0.38 | ||||
ERAS | Erasca | 0.67 | ||||
AVTE | Aerovate Therapeutics | 1.54 | ||||
ADAG | Adagene | 2.36 | ||||
CTMX | CytomX Therapeutics | 2.48 | ||||
ANTX | AN2 Therapeutics | 2.58 | ||||
ACHL | Achilles Therapeutics | 2.94 | ||||
MLYS | Mineralys Therapeutics, | 3.32 | ||||
CGEM | Cullinan Oncology | 3.43 | ||||
GPCR | Structure Therapeutics | 4.18 | ||||
IOBT | IO Biotech | 4.55 | ||||
AGIO | Agios Pharm | 5.76 | ||||
ASMB | Assembly Biosciences | 6.46 | ||||
TIL | Instil Bio | 8.88 | ||||
GLUE | Monte Rosa | 9.52 | ||||
ANEB | Anebulo Pharmaceuticals | 10.83 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |